Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Issue 11 (1st June 2010) - Raja, M S A; Saldana, M; Goldsmith, C; Burton, B J L